Initial report from the Hunter Outcome Survey. - Wikidata - awgldk - TriplyDB

Initial report from the Hunter Outcome Survey.

Initial report from the Hunter Outcome Survey.

http://www.wikidata.org/entity/Q44328956

about

Anaesthesia and airway management in mucopolysaccharidosis.Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).Growth charts for patients with Hunter syndrome.Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America.Impact of Enzyme Replacement Therapy and Hematopoietic Stem Cell Therapy on Growth in Patients with Hunter Syndrome.Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls Deep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome.Report of a Large Brazilian Family With a Very Attenuated Form of Hunter Syndrome (MPS II).Development of a mnemonic screening tool for identifying subjects with Hunter syndrome.Detection by Urinary GAG Testing of Mucopolysaccharidosis Type II in an At-Risk Spanish Population.Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome.Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome).Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients.Current and potential therapeutic strategies for mucopolysaccharidoses.Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.Management of the behavioural manifestations of Hunter syndrome.Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II.Growth in patients with mucopolysaccharidosis type III (Sanfilippo disease).Preventing mucopolysaccharidosis type II (Hunter syndrome): PGD and establishing a Hunter (46, XX) stem cell line.Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).Osteoarthropathy in mucopolysaccharidosis type II.Massive accumulation of glycosaminoglycans in the aortic valve of a patient with Hunter syndrome during enzyme replacement therapy.Challenges in the Management of Mucopolysaccharidosis Type II (Hunter's Syndrome) in a Developing Country: a Case Report.Hunter syndrome follow-up after 1 year of enzyme-replacement therapy Three Adult Siblings with Mucopolysaccharidosis Type II (Hunter Syndrome): A Report on Clinical Heterogeneity and 12 Months of Therapy with Idursulfase.Short stature with umbilical hernia - Not always due to cretinism: A report of two cases.Molecular analysis of the novel IDS allele in a Thai family with mucopolysaccharidosis type II: The c.928C>T (p.Gln310*) transcript is sensitive to nonsense-mediated mRNA decay.Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age.Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.Whole-exome sequencing expands the phenotype of Hunter syndrome.Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).

P2860

Q26996429-EC762075-7CA5-4A0A-946F-2743D78F27F7 Q33599445-256B4626-0608-49EF-AFA7-B353D9CF9FEE Q33630446-01C0FA30-5B5D-4076-AC33-B69D730468EF Q33660434-479B0CEA-4F4F-4543-B5D9-512A74517262 Q33768712-CE35434C-2F46-47FF-9996-B01F7F69DA99 Q33890337-CEF052E7-D79F-48AE-9367-1B2970235F80 Q33923815-D04E831B-4B26-429D-8730-638862CA1189 Q34002458-42D1E42E-7A56-4493-862A-5EEE5F271EFD Q34266971-73A1947C-CCF6-4434-A6A9-B7251AC0659F Q35128899-20BE7556-6736-4253-8D54-FB84E837D3C0 Q35559229-AD7373B2-48C3-4F3F-B4F5-6B8C44C3BD82 Q35571515-DFAADF0D-3781-41D4-9445-981ED53C8C51 Q35587435-9A00651E-83B7-406D-88B1-8E772904A0B7 Q35836716-D52BD260-8A37-4753-BC3C-665DD9E5B1F2 Q35848742-B4C0B02D-5A17-4D85-8DEA-C21C52D4923E Q36433429-5AED758C-279D-4E3A-8320-E02320FD325A Q36983261-7FB1A123-CC02-4295-AFB9-77A0018A6E63 Q37127684-AC482839-35E1-459D-BA53-A9DA7EF43529 Q37579048-41E3C0DB-55EA-4645-9211-8F65BA94A36C Q37583057-2B7BCCF8-619F-4F55-91B8-FFDF131DD520 Q37657164-2EFAE543-5C70-4CD7-BA57-BBA6AD374947 Q38194635-1F2A506D-FD29-409B-B0EA-400B0A4220D8 Q38634722-469B432B-4A69-4709-90A9-3450772DCE6D Q38696810-D3C438C5-8D1D-43EF-BA38-1927250683EB Q39156684-504099CD-9529-4082-A661-E5DDA7681CB6 Q39323860-0369D997-7872-418F-B6EE-ACE0058C5446 Q39517514-13984842-313E-4CDD-8F07-DCA8E3F87DD9 Q40049935-50B05354-14D8-4384-A369-54B793AE0556 Q40363011-0DED1BDD-375B-4B2A-BC76-73BF312DE4FF Q41827061-52E90680-D979-4522-899A-7B1446C7BFE9 Q41880549-A04D5815-6EA3-4968-B45C-C4DD55B1B478 Q41973861-484F53E0-C4F6-4AAC-A224-7A4F030758EC Q42130903-94107087-9C0B-498B-9792-72BD16C274CF Q42174157-A7FE66C3-A365-40D2-A09D-30791EE36AEF Q42235416-7ABACAB9-475B-4740-9E43-F4985D46F1F8 Q42281140-A50DB24F-4F5E-47B9-BAEB-A7906E89B54D Q42967269-749D5161-2D86-48AE-AEFB-423A8DF9E8D6 Q46150910-A8F031E0-B777-4F88-9791-AF1A9770FFBB Q46399321-EF526967-C9E7-4644-9B08-81893ADE9DE4 Q46869287-87EC241C-B669-478E-A804-3DBB7CF37B3F

P2860

Initial report from the Hunter Outcome Survey.

http://www.wikidata.org/entity/Q44328956

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Initial report from the Hunter Outcome Survey.

@en

Initial report from the Hunter Outcome Survey.

@nl

type

label

Initial report from the Hunter Outcome Survey.

@en

Initial report from the Hunter Outcome Survey.

@nl

prefLabel

Initial report from the Hunter Outcome Survey.

@en

Initial report from the Hunter Outcome Survey.

@nl

P1433

Q44328956-64442BA4-2A1C-4AEF-AEC4-CE58F8E57C8D

P1476

Q44328956-2BD19666-901A-4EB0-B752-073441910E22

P2093

Q44328956-009BA295-6572-4157-B628-6B81D52D6F84

Q44328956-5EF43EA1-8721-4771-AD91-D83BA4C38FA9

Q44328956-9B99AB30-2B27-4578-9B82-D213E371E0F5

Q44328956-A691A053-A36E-4471-B105-7236C83B8E27

Q44328956-B0C81800-C20A-4659-9235-9CFF6D5968AE

Q44328956-CD3D83EA-BCD2-4C54-BA34-13FFBDBDED30

Q44328956-E1CB75C2-38DA-4CF0-989B-68CB90E399B3

P2860

Q44328956-19CE94B6-3FE7-4A49-89C4-3CC631A647F5

Q44328956-1B84BFC8-9AD6-4F28-A44F-F26A36A6A52A

Q44328956-2F0A9999-9460-4DE7-BF55-2FCB2B6D4D72

Q44328956-2F0CE75A-70DA-43CD-AD04-879DDEF38D4E

Q44328956-38D5BA31-0176-4452-BB90-1E018D58D348

Q44328956-3E789AD3-4F19-4367-8FFE-979C80424646

Q44328956-3E831B0D-2BBD-4044-8056-02FE22C27F93

Q44328956-566DAB9D-0C37-4E68-8F14-0A1ACA37F017

Q44328956-69FB9B12-2604-46E2-8337-26804DCCF75F

Q44328956-735ED659-98D3-40E8-9081-2D3403B3F75D

P2888

Q44328956-3E94938D-4302-4C61-80AC-7333B2B2643D

P304

Q44328956-8337F040-2581-42A0-891B-DFE3A7003BA6

P31

Q44328956-B615AD46-87CB-4977-A0D6-BE98E9DD1D8F

P356

Q44328956-38063310-6578-44B9-9BF5-7896592A1937

P407

Q44328956-F321B6C7-75D8-4ED9-B36C-A00E00CE2F01

P433

Q44328956-23DFC89E-ABF8-44F8-9389-873DA5DB1B73

P478

Q44328956-D27AB0A2-5684-498A-BF38-4215B5193219

P577

Q44328956-66C4C62D-9508-4F1A-96FB-477B2A2196F7

P6179

Q44328956-36C20846-6DAD-4272-94F7-D763CC5D07AB

P698

Q44328956-6B676CFC-F29F-41A7-B57F-6D9A02E40AB2

P356

GIM.0B013E31817701E6

P1433

Genetics in Medicine

P1476

Initial report from the Hunter Outcome Survey.

@en

P2093

HOS Investigators

http://www.w3.org/2001/XMLSchema#string

J Edmond Wraith

http://www.w3.org/2001/XMLSchema#string

Joe Clarke

http://www.w3.org/2001/XMLSchema#string

Joseph Muenzer

http://www.w3.org/2001/XMLSchema#string

Michael Beck

http://www.w3.org/2001/XMLSchema#string

Rick Martin

http://www.w3.org/2001/XMLSchema#string

Roberto Giugliani

http://www.w3.org/2001/XMLSchema#string

P2860

The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

A clinical study of 77 patients with mucopolysaccharidosis type II

Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome

Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.

Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world.

The frequency of lysosomal storage diseases in The Netherlands.

Incidence of inborn errors of metabolism in British Columbia, 1969-1996.

P2888

gim.0b013e31817701e6

P304

508-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/GIM.0B013E31817701E6

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021254828

http://www.w3.org/2001/XMLSchema#string

P698

18580692

http://www.w3.org/2001/XMLSchema#string